Competitive Ligand Binding Assay for Neutralizing Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting neutralizing antibodies (NAbs) against biotherapeutics face challenges with sensitivity, specificity, matrix interference, assay variability, limited dynamic range, and lengthy durations, necessitating the development of more reliable and sensitive assays.
Innovation Solution
A non-cell based competitive ligand binding (CLB) assay using a labeled biotherapeutic protein as a capture reagent and a labeled soluble IL-6 receptor as a detection reagent, with a low pH treatment step to improve sensitivity and tolerance, is developed to detect NAbs in patient samples, specifically for sarilumab treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cell-based assays are used to detect neutralizing antibodies, then the ability to detect Nab activity is achieved, but the sensitivity and dynamic range are limited
Solution Approach 1:
The patent extracts the detection function from complex cell-based systems to a simplified non-cell-based competitive ligand binding assay. By removing cells and using only labeled reagents (labeled biotherapeutic and labeled target) in solution, the assay achieves superior sensitivity and dynamic range while eliminating cell-related variability and complexity
Solution Approach 2:
The patent replaces the biological cellular system with a chemical binding system. Instead of measuring cellular responses to biotherapeutic action, the assay uses direct ligand-receptor binding interactions between labeled biotherapeutic and labeled target, providing more precise and controllable measurements
2Measurement precision
If non-cell based competitive ligand binding assays are used, then superior dynamic range and sensitivity are achieved, but interference from assay and matrix components occurs
Solution Approach 1:
The patent applies preliminary acid treatment to patient samples before the assay to modify matrix components that cause interference. This pre-treatment step alters the chemical properties of interfering substances in the sample matrix, reducing their ability to interfere with the binding reactions while preserving the integrity of the antibody-antigen interactions
Solution Approach 2:
The patent introduces pH adjustment as an intermediary step between sample collection and assay execution. By controlling the pH environment, the assay mediates between the complex patient sample matrix and the sensitive binding reactions, creating optimal conditions that minimize interference while maintaining detection sensitivity
3Reliability
If current immunoassay methods are used, then neutralizing antibody detection is achieved, but the assay duration is lengthy
Solution Approach 1:
The patent extracts the essential detection function from lengthy multi-step immunoassay protocols to a streamlined competitive binding format. By removing unnecessary steps and using direct competition between labeled and unlabeled biotherapeutic for labeled target binding, the assay achieves rapid results with improved reliability
Solution Approach 2:
The patent skips intermediate processing steps found in traditional immunoassays by implementing a direct competitive binding format. The assay rushes through the detection process by having all components (labeled biotherapeutic, labeled target, and patient sample) interact simultaneously in a single competitive binding event, eliminating sequential washing and multiple incubation steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The assay achieves a sensitivity of 150 ng/mL, drug tolerance of 500 ng/mL, and target interference tolerance of 1 µg/mL, providing a precise and robust method for detecting NAbs with minimal interference, thereby enhancing the detection of neutralizing antibodies in clinical samples.
Implementation Method 1
combining a patient sample with a capture reagent, and adding a detection reagent wherein a decreased signal relative to a control sample indicates the presence of a neutralizing antibody to the biotherapeutic agent
Implementation Method 2
with a low pH treatment step to improve sensitivity and tolerance
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A immunogenicity assay for detecting the presence of neutralizing antibodies to a biotherapeutic protein wherein the biotherapeutic protein has been administered to a patient in need, comprising the steps of (a) obtaining a sample from the patient; (b) incubating the sample in the presence of a capture reagent; and (c) adding a detecting reagent, wherein a decreased signal relative to a control sample indicates the presence of a neutralizing antibody to the biotherapeutic agent.